All In Biotech

Drug Trial Radar · NCT06747858

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Dec 12, 2024

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Arcturus Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Conditions

  • Cystic Fibrosis
  • CFTR Gene Mutation

Interventions

  • ARCT-032Biological

    CFTR mRNA formulated in lipid nanoparticles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and dose relationship of adverse eventsTime frame: Cohorts 1-3: 16 weeks and Cohort 4: 24 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Children's Hospital of Los Angeles

    Los Angeles, California · Recruiting

  • Children's National Hospital

    Washington D.C., District of Columbia · Not yet recruiting

  • Joe DiMaggio Children's Hospital

    Hollywood, Florida · Recruiting

  • The Cystic Fibrosis Institute

    Northfield, Illinois · Active not recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • UT Health San Antonio

    San Antonio, Texas · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.